全文获取类型
收费全文 | 156篇 |
免费 | 1篇 |
专业分类
儿科学 | 3篇 |
基础医学 | 14篇 |
口腔科学 | 1篇 |
临床医学 | 53篇 |
内科学 | 28篇 |
皮肤病学 | 12篇 |
神经病学 | 2篇 |
外科学 | 20篇 |
综合类 | 1篇 |
预防医学 | 2篇 |
药学 | 19篇 |
肿瘤学 | 2篇 |
出版年
2017年 | 1篇 |
2014年 | 1篇 |
2013年 | 3篇 |
2010年 | 9篇 |
2009年 | 4篇 |
2008年 | 5篇 |
2007年 | 3篇 |
2006年 | 2篇 |
2003年 | 3篇 |
2002年 | 1篇 |
2001年 | 4篇 |
2000年 | 4篇 |
1999年 | 4篇 |
1998年 | 8篇 |
1997年 | 10篇 |
1996年 | 18篇 |
1995年 | 8篇 |
1994年 | 8篇 |
1993年 | 5篇 |
1992年 | 4篇 |
1991年 | 7篇 |
1990年 | 5篇 |
1989年 | 1篇 |
1988年 | 2篇 |
1987年 | 2篇 |
1986年 | 3篇 |
1985年 | 3篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1981年 | 3篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1977年 | 2篇 |
1976年 | 2篇 |
1972年 | 1篇 |
1971年 | 4篇 |
1970年 | 1篇 |
1968年 | 2篇 |
1958年 | 1篇 |
1957年 | 3篇 |
1956年 | 2篇 |
1955年 | 1篇 |
1954年 | 1篇 |
排序方式: 共有157条查询结果,搜索用时 15 毫秒
101.
Microfilarial clearance in loiasis involves elevation of Th1 and Th2 products and emergence of a specific pattern of T-cell populations 总被引:1,自引:0,他引:1
STEFAN WINKLER SABINE PAIHA HEIDI WINKLER WOLFGANG GRANINGER MICHAEL MARBERGER GEORG E. STEINER 《Parasite immunology》1996,18(9):479-482
Diethylcarbamazine (DEC) induced clearance of microfilaraemia in loiasis is associated with severe posttreatment reactions. To define the switch from hypo- to hyper-responsiveness associated with DEC treatment, phenotypic alterations of T-lymphocytes, characterized by flow cytometry, and cytokines, determined by enzyme linked immunosorbent assay, were monitored in a microfilaraemic patient. In contrast to reports on onchocerciasis and lymphatic filariases, no elevation of interleukin (IL)-6 and tumour necrosis factor (TNF)-α was observed. The most severe side effects coincided with an elevation of interferon (IFN)-γ on day 3, followed by IL-10, transforming growth factor (TGF)-β2 and macrophage inflammatory protein-1α (MIP-1α) peaking on day 5. Phenotypieally, T-cell activation markers CD38, CD54 and CD25 were significantly expressed before treatment, with high CD38 expression still existing one year after clearance of microfilaraemia. Treatment-related increases were observed with anti-CD 122, anti-HLA-DR and anti-CD69. CD28 was expressed before treatment on almost 100% qf'CD4+ and CD8+ T cells and dropped to 20% by day 5, reaching again baseline levels on day 21. Furthermore, there emerged 20% TCRαβ-/CD3+ T cells and 10%) anti-βV5(e) + T cells, altogether indicating a specific pattern of T-helper (Th)1 and Th2 cytokines as well as expansion of certain pauciclonal T-cell populations in response to microfilarial clearance. 相似文献
102.
Safety and Clinical Outcomes of Catheter Ablation of Atrial Fibrillation in Patients With Chronic Kidney Disease 下载免费PDF全文
ADITYA J. ULLAL B.A. DANIEL W. KAISER M.D. JUN FAN M.S. SUSAN K. SCHMITT Ph.D. CLAIRE T. THAN M.P.H. WOLFGANG C. WINKELMAYER M.D. M.P.H. Sc.D. PAUL A. HEIDENREICH M.D. M.S. JONATHAN P. PICCINI M.D. M.H.Sc. MARCO V. PEREZ M.D. PAUL J. WANG M.D. MINTU P. TURAKHIA M.D. M.A.S. 《Journal of cardiovascular electrophysiology》2017,28(1):39-48
103.
GEORGIOS J. VLACHOJANNIS M.D. STEPHAN FICHTLSCHERER M.D. IOAKIM SPYRIDOPOULOS M.D. WOLFGANG AUCH-SCHWELK M.D. BERND SCHOPOHL M.D. REAS M. ZEIHER M.D. VOLKER SCHÄCHINGER M.D. 《Journal of interventional cardiology》2010,23(1):60-65
Objective: The following retrospective observational study assesses the long-term results of intracoronary beta-radiation therapy for patients with in-stent restenosis.
Background: Beta-radiation has been used to treat patients with coronary in-stent restenosis. However, long-term clinical success using this technique has not at this time been established.
Methods: Two-hundred and thirteen consecutive patients received intracoronary brachytherapy (noncentered beta-emitter, Novoste BetaCath™) for in-stent restenosis and were followed up over a period of 39.1 ± 18.4 months. The combined end-point was defined as a major adverse clinical event (MACE) and comprised mortality, acute myocardial infarction, or target vessel revascularization (TVR).
Results: MACE occurred in 110 patients (51.6%): death in 27 patients (12.7%), acute myocardial infarction in 8 patients (3.8%), TVR in 90 patients (42.3%). TVR comprised percutaneous coronary reinterventions in 76 patients (35.7%) and coronary bypass surgery in 24 patients (11.3%). Secondary end-point was determined as target vessel failure and occurred in 93 patients (43.7%). Of note, the frequency of at least two previous target lesion interventions as well as impairment of left ventricular function was associated with reduced success rate, whereas other clinical parameters did not indicate outcome after treatment with intracoronary radiation therapy.
Conclusion: During the mean, a period of 3 years, more than half of the patients receiving intracoronary radiation therapy reached primary end-point, representing, in the main, TVR. During this period a mortality rate of nearly 13% was documented. These results signify a delayed, though continued, restenotic process after index procedure. (J Interven Cardiol 2010;23:60–65) 相似文献
Background: Beta-radiation has been used to treat patients with coronary in-stent restenosis. However, long-term clinical success using this technique has not at this time been established.
Methods: Two-hundred and thirteen consecutive patients received intracoronary brachytherapy (noncentered beta-emitter, Novoste BetaCath™) for in-stent restenosis and were followed up over a period of 39.1 ± 18.4 months. The combined end-point was defined as a major adverse clinical event (MACE) and comprised mortality, acute myocardial infarction, or target vessel revascularization (TVR).
Results: MACE occurred in 110 patients (51.6%): death in 27 patients (12.7%), acute myocardial infarction in 8 patients (3.8%), TVR in 90 patients (42.3%). TVR comprised percutaneous coronary reinterventions in 76 patients (35.7%) and coronary bypass surgery in 24 patients (11.3%). Secondary end-point was determined as target vessel failure and occurred in 93 patients (43.7%). Of note, the frequency of at least two previous target lesion interventions as well as impairment of left ventricular function was associated with reduced success rate, whereas other clinical parameters did not indicate outcome after treatment with intracoronary radiation therapy.
Conclusion: During the mean, a period of 3 years, more than half of the patients receiving intracoronary radiation therapy reached primary end-point, representing, in the main, TVR. During this period a mortality rate of nearly 13% was documented. These results signify a delayed, though continued, restenotic process after index procedure. (J Interven Cardiol 2010;23:60–65) 相似文献
104.
RALF HOFFMANN INGMAR REICHERT WOLFGANG O. WACHS MICHAEL ZEPPEZAUER HANS ROBERT KALBITZER 《Chemical biology & drug design》1994,44(3):193-198
The model peptides glycylglycyltyrosylalanine (Gly-Gly-Tyr-Ala), glycylglycylthreonylalanine (Gly-Gly-Thr-Ala) and glycylglycylserylalanine (Gly-Gly-Ser-Ala) were phosphorylated at the hydroxyl groups of their tyrosyl, threonyl and seryl residues, respectively, and characterized by 31P and 1H NMR spectroscopy. The pKa-value of the phosphoryl group in the tyrosine-containing peptide determined from the pH dependence of chemical shifts is 5.9, the 31P chemical shifts at low pH (4.0) and high pH (8.0) are -3.8 and 0.2 ppm, respectively. Phosphorylation also leads to significant shifts of the 1H NMR resonances of the tyrosine residue; the amide resonance is shifted -0.02 ppm, the Hα resonance 0.06 ppm, the Hβ resonances 0.10 and -0.04 ppm, the H§ resonances 0.02 ppm and the Hω resonances 0.26 ppm. The pKa-value of the phosphoryl group in the threonine peptide determined from the pH dependence of chemical shifts is 6.1; the 31P chemical shifts at low pH (4.0) and high pH (8.0) are -0.1 and 4.8 ppm, respectively. The corresponding values for the serine peptide are 6.1 (pKa), 0.6 ppm and 4.9 ppm. Phosphorylation also leads to significant shifts of the 1H NMR resonances of the threonine and serine residues. In the threonine residue the amide resonance is shifted 0.25 ppm, the Hα-resonance -0.43 ppm, the Hβ-resonance 0.03 ppm and the Hγ-resonance 0.09 ppm. In the serine residue the amide resonance is shifted 0.21 ppm, the Hα-resonance -0.17 ppm, and the Hβ-resonances 0.17 ppm. 相似文献
105.
106.
A method to incorporate N-chloroacetyl moieties at the amino termini of synthetic peptides using a standard program with an automated peptide synthesizer has been developed. The N-chloroacetyl-modified peptides react well with sulfhydryl containing proteins such as 4-mercaptobutyrimide-modified bovine serum albumin to form stable protein-peptide conjugates. By incorporating cysteine into the synthetic peptide, autopolymerization or cyclization of the synthetic peptide occurs by reaction of the free sulfhydryl with the chloroacetyl group. N-Chloroacetyl-derivatized peptides may be useful as reagents for potential peptide immunogens and vaccines. 相似文献
107.
J
RG METZGER KARL-HEINZ WIESMÜLLER RENATE SCHAUDE WOLFGANG G. BESSLER GÜNTHER JUNG 《Chemical biology & drug design》1991,37(1):46-57
The synthesis and characterization of lipopeptides consisting of the lipoamino acid N-palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-[R]-cysteine (Pam,Cys-OH) and different peptide segments and/or spacer molecules is described. Pam,Cys-peptides, which are derived from the immunologically active TV-terminus of bacterial lipoprotein, were obtained either by solution or solid phase peptide synthesis. In particular, the amphiphilic and water-soluble lipohexapeptides Pam3Cys-Ser-(Lys)4 and Pam3Cys-Ser-(Glu)4 proved to be potent macrophage and B-cell activators and non-toxic, non-pyrogenic immune adjuvants in combination with or covalently linked to antigens and haptens. 相似文献
108.
HANSJ
RG DÜRR ANNETTE G. BECK-SICKINGER GERD SCHNORRENBERG WOLFGANG RAPP GÜNTHER JUNG 《Chemical biology & drug design》1991,38(2):146-153
Kinetics and cleavage conditions of peptide amide synthesis were studied using the anchor molecules 5-(4′-aminomethyl-3′,5′-dimethoxyphenoxy)valeric acid (4-ADPV-OH) and 5-(2′-aminomethyl-3′,5′-dimethoxyphenoxy)valeric acid (2-ADPV-OH). Unexpectedly the anchor amide alanyl-4-ADPV-NH2 was isolated and characterized as an intermediate during the cleavage with trifluoroacetic acid (TFA) of alanyl-4-ADPV-alanyl-aminomethyl-polystyrene to yield the alanine amide. As a matter of fact the NH–CHα bond of the alanyl spacer has to be cleaved to form this intermediate. Using TFA-dichloro-methane (1:9) alanyl-4-ADPV-NH2 was obtained as a cleavage product in 50% yield within 60min, whereas the isomeric alanyl-2-ADPV-NH2 was formed more slowly under these mild conditions. At high TFA concentration no difference between the 2- and 4-ADPV anchor was observed in the rate of formation of the free alanine amide. The presence of tryptophan amide in the cleavage mixture resulted in an anchor alkylated tryptophan amide, which remains stable in acidic solution but disappears rapidly in the presence of the resin. A low TFA/high TFA cleavage procedure is recommended for peptide amid synthesis applying the ADPV anchor. 相似文献
109.
110.
SIMON PANZER LEO AUERBACH EVA CECHOVA GOTTFRIED FISCHER ANDREA HOLENSTEINER EVA-MARIA KITTL WOLFGANG RICHARD MAYR MICHAEL POTZ PETER WAGENBICHLER SABINE WALCHSHOFER 《British journal of haematology》1995,90(3):655-660
Summary. Neonatal alloimmune thrombocytopenia (NAIT) is induced by maternal alloantibodies to fetal platelet antigens. This prospective study was carried out to evaluate the incidence of anti-platelet antibodies in 933 mother-child pairs where the mother and child were typed for the human platelet antigens (HPA)-l, -2,-3,-5. Sera from mismatched mother-child pairs were screened for anti-platelet antibodies, anti-HLA class I and blood group ABO IgG antibodies. Platelet-specific antibodies were anti-HPA-3a in one and anti-HP A-5b in 17 neonates, respectively. All these neonates had normal platelet counts. One woman had autoreactive antibodies. Anti-HLA class I and anti-blood group A IgG antibodies were detected in five and four neonates, respectively, born with a platelet count <150×109/l. None of the 11 homozygous HP A-lb mothers became immunized against their heterozygous offspring. The maternal HLA-allotypes HLA-DR52 and -DR6, typically found in individuals immunized against HPA-la and -5b, respectively, were found in three of 11 HPA-b/b non-responders and eight of the anti-HPA-5b responders. The results indicate that a risk for NAIT due to HPA-2 and -3 alloimmunization is low. The HLA allotypes do not predict the risk for NAIT due to HPA-1 or -5 alloimmunization. Maternal anti-HPA-5b antibodies do not correlate with the platelet count in the neonate. 相似文献